Association Between the Use of Psychotropic Medications and the Risk of COVID-19 Infection Among Long-term Inpatients With Serious Mental Illness in a New York State–wide Psychiatric Hospital System
MD Katlyn Nemani, DrPH Sharifa Z Williams, MD Mark Olfson, PhD Emily Leckman-Westin, MD Molly Finnerty, PhD Jammie Kammer, MD Thomas E Smith, MD; Daniel J Silverman, MD Jean-Pierre Lindenmayer, BS Gillian Capichioni, PhD; James Clelland, MD Donald C Goff
JAMA Network Open, doi:10.1001/jamanetworkopen.2022.10743
IMPORTANCE Individuals with serious mental illness are at increased risk of severe COVID-19 infection. Several psychotropic medications have been identified as potential therapeutic agents to prevent or treat COVID-19 but have not been systematically examined in this population. OBJECTIVE To evaluate the associations between the use of psychotropic medications and the risk of COVID-19 infection among adults with serious mental illness receiving long-term inpatient psychiatric treatment. DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study assessed adults with serious mental illness hospitalized in a statewide psychiatric hospital system in New York between March 8 and July 1, 2020. The final date of follow-up was December 1, 2020. The study included 1958 consecutive adult inpatients with serious mental illness (affective or nonaffective psychoses) who received testing for SARS-CoV-2 by reverse transcriptase-polymerase chain reaction or antinucleocapsid antibodies and were continuously hospitalized from March 8 until medical discharge or July 1, 2020. EXPOSURES Psychotropic medications prescribed prior to COVID-19 testing. MAIN OUTCOMES AND MEASURES COVID-19 infection was the primary outcome, defined by a positive SARS-CoV-2 reverse transcriptase-polymerase chain reaction or antibody test result. The secondary outcome was COVID-19-related death among patients with laboratory-confirmed infection.
RESULTS Of the 2087 adult inpatients with serious mental illness continuously hospitalized during the study period, 1958 (93.8%) underwent testing and were included in the study; 1442 (73.6%) were men, and the mean (SD) age was 51.4 (14.3) years. A total of 969 patients (49.5%) had laboratory-confirmed COVID-19 infection that occurred while they were hospitalized; of those, 38 (3.9%) died. The use of second-generation antipsychotic medications, as a class, was associated with decreased odds of infection (odds ratio [OR], 0.62; 95% CI, 0.45-0.86), whereas the use of mood stabilizers was associated with increased odds of infection (OR, 1.23; 95% CI, 1.03-1.47). In a multivariable model of individual medications, the use of paliperidone was associated with decreased odds of infection (OR, 0.59; 95% CI, 0.41-0.84), and the use of valproic acid was associated with increased odds of infection (OR, 1.39; 95% CI, 1.10-1.76). Clozapine use was associated with reduced odds of mortality in unadjusted analyses (unadjusted OR, 0.25; 95% CI, 0.10-0.62; fully adjusted OR, 0.43; 95% CI, 0.17-1.12). (continued) Key Points Question Is psychotropic medication use associated with differences in the risk of COVID-19 infection among adults with serious mental illness? Findings In this cohort study of 1958 inpatients with serious mental illness in a statewide psychiatric hospital system, the use of second-generation antipsychotic medications was associated with a decreased risk of COVID-19 infection; the largest association was observed with the use of..
Author Contributions: Drs Nemani and Goff had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Nemani, Williams, Olfson, Finnerty, Clelland, Goff. Acquisition, analysis, or interpretation of data: Nemani, Williams, Leckman-Westin, Finnerty, Kammer, Smith, Silverman, Lindenmayer, Capichioni, Goff. Drafting of the manuscript: Nemani, Williams, Capichioni, Goff. Critical revision of the manuscript for important intellectual content: Nemani, Williams, Olfson, Leckman-Westin, Finnerty, Kammer, Smith, Silverman, Lindenmayer, Clelland, Goff.
Statistical analysis: Williams. Administrative, technical, or material support: Finnerty, Smith, Silverman, Lindenmayer, Capichioni, Goff. Supervision: Leckman-Westin, Finnerty, Smith, Goff.
Conflict of Interest Disclosures: Dr Lindenmayer reported receiving grants from Roche, Takeda, Lundbeck, Avanir, GW/Jazz, Neurocrine, and the National Institute of Mental Health outside the submitted work; and having a patent for the Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) with royalties paid. No other disclosures were reported.
References
Gordon, Hiatt, Bouhaddou, Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms, Science,
doi:10.1126/science.abe9403Govind, Fonseca De Freitas, Pritchard, Hayes, Maccabe, Clozapine treatment and risk of COVID-19 infection: retrospective cohort, Br J Psychiatry,
doi:10.1192/bjp.2020.151Gul, Ozcan, Asar, Okyar, Barıs et al., In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials, J Biomol Struct Dyn,
doi:10.1080/07391102.2020.1802346Hoertel, Sánchez-Rico, Gulbins, Entrepôt de Données de Santé" AP-HP Consortium. Association between FIASMAs and reduced risk of intubation or death in individuals hospitalized for severe COVID-19: an observational multicenter study, Clin Pharmacol Ther,
doi:10.1002/cpt.2317Hoertel, Sánchez-Rico, Vernet, /Universities/INSERM COVID-19 research collaboration and AP-HP COVID CDR Initiative. Observational study of haloperidol in hospitalized patients with COVID-19, PLoS One,
doi:10.1371/journal.pone.0247122Hoertel, Sánchez-Rico, Vernet, AP-HP/Universities/INSERM COVID-19 Research Collaboration and AP-HP COVID CDR Initiative. Observational study of chlorpromazine in hospitalized patients with COVID-19, Clin Drug Investig,
doi:10.1007/s40261-021-01001-0Hoertel, Sánchez-Rico, Vernet, Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study, Mol Psychiatry,
doi:10.1038/s41380-021-01021-4Hosmer, Lemeshow, Sturdivant, Applied Logistic Regression
Kennedy, Richeson, Houde, Psychiatry Association Between Psychotropic Medication Use and COVID-19 Risk, N Engl J Med,
doi:10.1056/NEJMc2029354Maine, Lao, Krishnan, Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect, J Clin Virol,
doi:10.1016/j.jcv.2020.104663Mcmichael, Currie, Clark, Public Health-Seattle and King County, EvergreenHealth, and CDC COVID-19 Investigation Team. Epidemiology of Covid-19 in a long-term care facility in King County, Washington, N Engl J Med,
doi:10.1056/NEJMoa2005412Okusaga, Mitchell, Bernard, Walder, Clozapine is associated with higher COVID-19 infection rate in veterans with schizophrenia or schizoaffective disorder, J Clin Psychiatry
Pandurangi, Buckley, Inflammation, antipsychotic drugs, and evidence for effectiveness of antiinflammatory agents in schizophrenia, Curr Top Behav Neurosci,
doi:10.1007/7854_2019_91Pitt, Sutton, Wang, Goonewardena, Holinstat, Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19, Eur J Pharmacol,
doi:10.1016/j.ejphar.2021.173988Prokopez, Farinola, Vallejos, Olanzapine, risperidone and quetiapine: do these atypical antipsychotics have a protective effect for SARS-CoV-2?, Schizophr Res,
doi:10.1016/j.schres.2022.01.035Prokopez, Vallejos, Lopredo, An analysis of the possible protective effect of antipsychotics for SARS-CoV-2 in patients under treatment for severe mental illnesses, Schizophr Res,
doi:10.1016/j.schres.2021.06.019Reis, Santos Moreira-Silva, Silva, Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial, Lancet Glob Health,
doi:10.1016/S2214-109X(21)00448-4Smith, Rodgers, Silverman, COVID-19 case rates after surveillance and vaccinations in a statewide psychiatric hospital system, Am J Public Health,
doi:10.2105/AJPH.2021.306444Stip, Arnone, Aziz, Javaid, Diversity of mechanism of action of psychotropic drugs in their anti-COVID-19 properties, Mol Psychiatry,
doi:10.1038/s41380-021-01222-xSukhatme, Reiersen, Vayttaden, Sukhatme, Fluvoxamine: a review of its mechanism of action and its role in COVID-19, Front Pharmacol,
doi:10.3389/fphar.2021.652688Supplement, Efigure, Study Profile eTable 1. Psychotropic Medications Exposure in Full Cohort and by Infection and Death eTable 2. ICD-9/10 Category Codes Used to Identify Medical Conditions and Psychiatric Diagnoses eTable 3. Incidence and Adjusted Odds Ratios of COVID-19 Infection by Psychotropic Medication Exposure in Patients with PCR Testing
Tzur Bitan, Krieger, Kridin, COVID-19 prevalence and mortality among schizophrenia patients: a largescale retrospective cohort study, Schizophr Bull,
doi:10.1093/schbul/sbab012Vai, Mazza, Colli, Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis, Lancet Psychiatry,
doi:10.1016/S2215-0366(21)00232-7Vieira, Nery, Martins, Jabour, Dias et al., Downregulation of membrane-bound angiotensin converting enzyme 2 (ACE2) receptor has a pivotal role in COVID-19 immunopathology, Curr Drug Targets,
doi:10.2174/1389450121666201020154033Wang, Xu, Volkow, Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States, World Psychiatry,
doi:10.1002/wps.20806Yang, Kandula, Huynh, Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis, Lancet Infect Dis,
doi:10.1016/S1473-3099(20)30769-6
